Brazil’s former President Luiz Inacio Lula da Silva has said he is willing to stand as a candidate in elections against incumbent leader Jair Bolsonaro, labelling his potential opponent “a poor copy of Trump.”
Speaking in Brussels at a media conference in the European Parliament on Monday, Lula announced that the Workers Party needs to put forward a presidential candidate to take over from right-wing Bolsonaro in 2022 and said he was willing to run in the elections again.
“I’m willing, I’m motivated, I’m in good health,” Lula stated, adding that said he would only make his decision early next year, some months before the election scheduled for October 2022. The popular leftist said his candidacy would depend on whether the party wanted him.
“We need to have someone who stands, we need to win the elections. And at the same time, we have to rebuild Brazil,” he said, speaking on behalf of his Workers Party.
Lula, 76, also took aim at the incumbent president. “He’s a poor copy of Trump. But Bolsonaro doesn’t think, he doesn’t have any ideas,” the former president said, claiming the incumbent leader was hellbent on ensuring the beneficial legacies of Lula’s administration were “torn down.”
A recent poll put him 27 points ahead of Bolsonaro, despite his candidacy not officially being announced.
In 2010, Lula made way for his protégé, Dilma Rousseff. Rousseff was ousted from power in what was described by her supporters as a parliamentary coup. Lula served nearly two years in prison after being convicted on money laundering and corruption, despite a nine-and-a-half-year sentence. He was also barred from running in the 2018 election.
A number of judges have subsequently ruled that the case against Lula was unlawful and the Supreme Court annulled his earlier convictions, meaning he can face off against Bolsonaro in 2022.
Two climate activists in Australia have brought the world’s busiest coal port to a halt, strapping themselves to a massive piece of machinery and refusing to come down. The stunt follows more than a week of similar actions.
Blockade Australia, a climate group focused on “strategic direct action,” declared that two of its members had clambered atop equipment at the Port of Newcastle and stopped work there late Tuesday night, sharing footage captured by the activists as they suspended themselves from a large loading machine.
“Zianna and Hannah have shut down Newcastle coal port, abseiling from coal handling machinery. The port cannot resume operations until the pair are removed by police,” the group said, identifying the activists by their first names only, adding “This is the tenth consecutive day of disruption to Newcastle coal port and its supply rail network.”
The protest stunt follows at least 16 similar actions over the last week or so, the group said, some targeting the rail line near the port, the world’s largest for coal exports.
Another demonstration carried out on Tuesday saw a second pair of activists breach the port and “hit emergency stop buttons” on machines before strapping themselves to a different piece of equipment. They were brought down and arrested after “several hours” and are expected to appear in court in the coming days.
The disruptions have drawn the ire of state officials, with New South Wales Environment Minister Matt Kean calling them “completely out of line” and urging police to “throw the book” at the protesters, at least 19 of whom have already been arrested so far this month, according to ABC.
“Pull your heads in, get out of the way and stop hurting other people going about their lives, running their businesses,” the minister said during a radio interview on Wednesday. “There are hundreds of ways to make your views known and advocate for change, but risking the lives of rail workers is definitely not one of them.”
The activists could face charges that carry maximum sentences of 25 years in prison, NSW police commissioner Mick Fuller said, noting that local law enforcement has created a “strike force” to deal with future disturbances at the port.
The Chinese foreign ministry has lashed out at Lithuania after the small Baltic Sea nation approved the opening of the Taiwan Representative Office in Vilnius. Beijing says it undermines its One China policy.
Beijing was disappointed that Lithuania had proceeded to grant Taiwan permission to open its ‘representative office’ in Vilnius despite “China’s strong opposition and repeated persuasion,” Chinese foreign ministry spokesman Zhao Lijian said at a press briefing on Friday. Taiwan had opened its mission in Vilnius the previous day.
Zhao called the move a violation of the One China principle, which he said is undermining China’s sovereignty and territorial integrity, while grossly interfering in its internal affairs. The spokesman reminded Lithuania that Taiwan is an inalienable part of China’s territory and the Beijing government has sole legal authority.
As to what necessary measures China will take, you may wait and see. The Lithuanian side shall reap what it sows.
In a “stern warning” to the Taiwanese authorities, Zhao then added that “seeking ‘Taiwan independence’ by soliciting foreign support is a totally misguided attempt that is doomed to fail.”
In August, Lithuania announced that the diplomatic outpost would be named the “Taiwan Representative Office,” angering China. Taiwan’s diplomatic branches – in countries that have de facto relations with the island’s authorities – are normally called “Taipei Economic and Cultural Offices.”
China demanded that Lithuania recall its ambassador from China, which it did. Beijing then withdrew its envoy to the Baltic state.
Chinese officials have repeatedly called on Western nations, notably the UK and US, to stop interfering in Beijing’s internal affairs, stressing that they consider Taiwan to be part of China.
Scientists in Sweden claim that a single protein in the blood could predict the onset of Type 2 diabetes nearly 20 years in advance. The breakthrough potentially affects hundreds of millions of people worldwide.
Diabetes is the world’s ninth-leading cause of death, and affects nearly half a billion people worldwide, according to the World Health Organisation (WHO). The vast majority of diabetes patients suffer from Type 2 diabetes, a condition that can lead to blindness, kidney failure, heart attacks, strokes, and lower limb amputation. Cases of diabetes quadrupled worldwide between 1980 and 2014, with unhealthy diets and lack of exercise blamed for the rise.
However, researchers at Lund University in Malmo, Sweden claim that elevated levels of a certain protein – follistatin – in the blood can predict the onset of Type 2 diabetes regardless of a person’s age, weight, diet or activity level. In a study published last week, the scientists wrote that high levels of follistatin can predict the condition up to 19 years before symptoms appear.
To discover the link between follistatin and diabetes, the researchers tracked 5,300 people from Sweden, Italy, and the UK for between four and 19 years. Follistatin helps break down body fat, while simultaneously leading to an increase in fat in the liver. This buildup can cause fatty liver disease and Type 2 diabetes.
“This study shows that follistatin has the potential to become an important biomarker to predict future Type 2 diabetes, and it also brings us one step closer to the understanding of the mechanisms behind the disease,” Dr. Yang De Marinis, associate professor at Lund University and lead author of the study, told a university newsletter. De Marinis added that the next step for her team would be to help develop an AI-based diagnostic tool that could analyze a patient’s blood sample and use their follistatin levels – and other biomarkers – to calculate their “risk score” for Type 2 diabetes.
As follistatin levels rise in response to food intake and activity levels, the same advice for prevention of diabetes still applies. “Balanced meals, eat[ing] healthy and regular exercise are important to decrease the risk of developing Type 2 diabetes,” De Marinis told StudyFinds.
Think your friends would be interested? Share this story!
American billionaire Bill Gates has claimed Covid-19 deaths and infections may drop below seasonal flu levels next year as more people get vaccinated and treatment improves, unless we encounter a new, more deadly variant.
Speaking on Thursday in a virtual interview at the Bloomberg New Economy Forum in Singapore, founder of Microsoft stated that vaccines, natural immunity and emerging oral treatments mean that “the death rate and the disease rate ought to be coming down pretty dramatically.”
The tech mogul, who has been particularly vocal during the pandemic, said issues around vaccine-production capacity are likely to be replaced by distribution challenges and even waning demand.
“The vaccines are very good news, and the supply constraints will be largely solved as we get out in the middle of next year, and so we’ll be limited by the logistics and the demand,” he noted.
He also told his audience that it remains to be seen how much demand there is for Covid-19 shots in places like Sub-Saharan Africa.
Calling for more work to eradicate flu, Gates claimed Covid-19 rates and deaths would possibly fall below those of flu by the middle of next year, unless more deadly coronavirus variants emerge.
The Bill and Melinda Gates Foundation has involved itself in the development of vaccines and virus surveillance, calling for a global response to the Covid-19 pandemic. The foundation has invested hundreds of millions dollars in the development and distribution of potentially lifesaving shots.
According to the World Health Organization, influenza kills up to 650,000 people each year. At least five million people have died from Covid-19 since the pandemic began in late 2019.
An American nonprofit behind the US-funded bat virus research in China has denied sending virus samples from Laos – where the closest natural relative of SARS-CoV-2 was found – to Wuhan in response to new allegations.
“No work was ever conducted in Laos as a part of this collaborative research project,” EcoHealth Alliance – a group that conducted experiments on coronaviruses while receiving funding from the National Institutes of Health (NIH) – said in a series of tweets on Sunday, responding to media reports alleging that the group might have transported a potentially dangerous virus from Laos to the laboratory in Wuhan.
However, we considered it a higher priority to continue our focus on China, and no work was ever conducted in Laos as a part of this collaborative research project.
The group’s name surfaced in October when the NIH’s principal deputy director, Lawrence Tabak, revealed that EcoHealth Alliance did experiments on the viruses with the agency’s financial help. At the time, White House medical adviser Dr. Anthony Fauci stated that the viruses “were distant enough molecularly that no matter what you did to them, they could never, ever become SARS-CoV-2.”
EcoHealth Alliance has come under renewed scrutiny after emails obtained through a Freedom of Information request appeared to indicate that the group was discussing the possibility of collecting viral samples from bats in Laos and sending them to the Wuhan Institute of Virology. The emails were initially obtained by the White Coat Waste Project and sparked a flurry of reports over the weekend, including in the Spectator by British science writer Matt Ridley.
The emails shared between EcoHealth Alliance and its US government funders reportedly reveal that the scientists discussed collecting viral samples from bats in eight countries, including in Laos, between 2016 and 2019, and toyed with the idea of transporting them to Wuhan – apparently, to avoid red tape. One email from 2016 cited by the Spectator reportedly reads: “All samples collected would be tested at the Wuhan Institute of Virology.”
Laos is the birthplace of at least one virus that seems to be very close to SARS-Cov-2. A bat viral strain called Banal-52 discovered in Laos in September shares 96.8% of its genome with the virus behind the Covid-19 pandemic
On Sunday, EcoHealth Alliance claimed that the emails cited by Ridley “do not show… that we were sampling bats in Laos and sending the results to Wuhan.”
The group acknowledged, however, that it requested NIH permission to work in Southeast Asian countries, including Laos, and that permission was granted.
However, the nonprofit claimed it ended and focused on China instead.
The response was not satisfactory for Ridley, who is also the co-author of a book on the origins of Covid-19, and he has demanded evidence showing that his report was not “fully accurate.”
As infections are rising again, scientists all around the world are rushing to fight the danger, offering a choice of new treatments and unusual variants of vaccines.
Levels of contagion are setting new records, hospitals are overwhelmed, governments are starting to introduce lockdowns, and not only for unvaccinated people – the picture of the fight against Covid-19 looks quite disappointing. However, there’s still a place for good news: Research teams report positive results while trialling new medicines and vaccine types.
Nasal vaccines
Vaccination will remain one of the most effective tools against Covid-19. As Professor David Dockrell, from the Center for Inflammation Research of the University of Edinburgh, told RT, “vaccines will continue to be a central part of how we control the virus.”
“If we can dampen down the number of infections, and the severity of infections, and also the extent to which the virus can replicate in people when they become infected, then we are slowing down the ability of the virus to change and to mutate,” he explains.
So I think the vaccines still will be a very important part of the preventive strategy. It’s vital that they are available to all the world’s population, irrespective of where people live, and the wealth of the country in which they live.
However, vaccination doesn’t always mean you have to get an injection. For instance, several intranasal Covid-19 vaccines are currently being developed. As the virus gets into the body through the nose, a nasal spray or drops are aimed to produce mucosal immune response and prevent it from getting into the lungs.
In India, a vaccine of this type is already completing Phase 2 of clinical trials. In Russia, a nasal vaccine is undergoing a clinical trial on volunteers. In Thailand, a home-developed product is expected to be trialed on humans next spring. In the US, Universities of Houston and Stanford recently reported good results of their experiments carried out on mice.
Intranasal vaccines can have several potential benefits compared to inoculation.
“They would be easier to use, because they can be self-administered. They wouldn’t need a nurse or clinical settings,” Swedish professor emeritus of epidemiology Marcello Ferrada de Noli explained to RT. As a result, he says, there’s hope that fewer people will be reluctant to be immunized. Not so many of us find it pleasant to get a jab – and after all, there are those who are just afraid of needles. Also, it would be much easier to vaccinate children with nasal substances.
However, what concerns Prof. de Noli the most is the duration of the effect of a vaccine of this type. Still, scientists can’t say for sure whether a nasal substance may completely replace a shot. According to Alexander Gintsburg, the head of Moscow’s Gamaleya Center biomedical research institute, which created the Sputnik V vaccine, the nasal version they are working on would serve for an additional protection against the virus, but would not replace the injections.
Chew the virus away?
A nasal vaccine is not the only one being developed. In summer, it was revealed that Russian Defense Ministry scientists were creating a ‘chewing gum’ vaccine, also targeting the mucosal immune response. Meanwhile, a UK firm announced this month that it would conduct a human trial of a skin patch that uses T-cells to confront the virus. Developers hope it would offer longer-lasting immunity than the existing vaccines. Work on a similar project is being done in the University of Queensland, Australia.
While it all looks so promising, Prof. de Noli warns that it would still take a lot of time until these products become available to the public. “I think that discoveries in this field are a very good thing. But if we say ‘We discovered a new type of vaccine’, people will say ‘Aha, so I’m going to wait’. But we need to vaccinate people now,” he points out.
Improving Covid treatment
Vaccines are not a silver bullet, unfortunately, given the not-so-high level of global immunization and the constantly emerging new strains of the virus. “People might get infected despite having had a vaccine, but I still think the vaccine strategy is going to be central to how we manage this kind of virus going forward,” Prof. Dockrell says. “But we will have other strategies that will be very important. We will have other elements. When we put them all together, it gives us the best opportunity that people can live with coronaviruses, and hopefully, the mortality can be limited to much lower extense than what we’ve sadly seen in the last eighteen months.”
Monoclonal antibodies will be central to the ongoing vaccine strategy, Prof. Dockrell explains. These are the antibodies similar to those the body uses to fight the virus. They are produced in labs and given via infusion or injection to boost the patient’s response against certain diseases. Monoclonal antibody treatment is used for people under a high risk of developing severe infection (including older patients 65+ years old or those with chronic medical conditions). It’s already being used in the US, following last year’s FDA approval. Earlier in November, the European Medicines agency recommended authorizing two monoclonal antibody medicines.
In October, UK’s AstraZeneca reported positive results of a Phase 3 study of its antibody combination, which, according to developers, is highly effective in both prevention and treatment of coronavirus.
Researchers are also working on a possibility to save Covid-infected patients from the so-called ‘cytokine storm’ – a situation when the immune system reacts so intensely that kills not only the virus, but the whole organism itself. A drug to ‘calm the storm’ was registered in Russia this year, and it’s already being used on patients.
Another way to fight Covid-19 is to use antiviral drugs. When the pandemic started, medics had to use something already existing (like anti-influenza Favipiravir) or something being authorized for emergency use (like remdesivir). Now, more than a year on, the work to create a special drug to specifically cure Covid-19 is giving its results. This month, Russia registered its first injectable anti-Covid medicine. A bit earlier, the UK became the first country to approve an antiviral pill produced by the US-based companies Merck and Ridgeback Biotherapeutics. Another American firm, Pfizer, got positive results from trials of its drug of the same kind. Both firms hope that with a drug in the form of a pill it would be easier to treat people at home.
Appreciating all the efforts on the field of developing anti-Covid treatment, Prof. de Noli points out that still, the key issue now is to reduce the spreading of the virus. “The new medicines are developed for people who already got the disease,” he says.
But we need to prevent people from getting the infection, not let them get infected because we have some new medicine that can cure them.
The same idea is echoed by scientists all over the world quoted in plenty of articles dedicated to the medical gains: it’s great to have the treatment, but none of the drugs may substitute vaccination, as first and foremost, humanity has to adopt preventive measures and stop the pandemic.
The EU’s drug regulator has backed the emergency use of Merck’s pill for the treatment for clinically vulnerable Covid-19 patients as cases surge across the continent.
On Friday, the European Medicines Agency (EMA) “issued advice” backing the emergency use of the drug developed by Merck in collaboration with Ridgeback Biotherapeutics, although it has not yet been authorized by national authorities.
In a statement, the drug regulator said the medicine called Lagevrio – also known as molnupiravir or MK 4482 – “can be used to treat adults with Covid-19 who do not require supplemental oxygen and who are at increased risk of developing severe Covid-19.”
It said the treatment should be administered as soon as possible after Covid-19 is diagnosed and within five days of the start of symptoms. The medicine should be taken twice a day for a period of five days.
The EMA listed the potential side effects of the capsules, including mild or moderate diarrhea, nausea, dizziness and headache. The treatment is not recommended for pregnant women.
The watchdog announced earlier on Friday that it had begun reviewing Pfizer’s medicine Paxlovid for Covid-19 with the same goal “to support national authorities” who may decide on its early use prior to marketing authorization in light of rising cases and deaths in Europe.
On Friday, Austria announced it would enter a new nationwide lockdown from Monday and make vaccination mandatory, while Germany’s health authorities claimed the country had turned into “one big outbreak.”
Both Pfizer and Merck have requested approval for their coronavirus medicines from the US Food and Drug Administration, but it is unclear when it might be granted.
Think your friends would be interested? Share this story!
A stream literally flowing with booze emitting a strong beery odor has been discovered in one of the tropical islands of Hawaii. Its waters have been apparently contaminated with alcohol after a leak at a beverage warehouse.
A small river with a distinctive alcoholic smell was recently found on the island of Oahu, some 15 miles (24 kilometers) away from Honolulu, Hawaiian capital. Its waters have been flowing through the Waipio valley and even turned into a 100-foot (30 meters) waterfall on their way.
The stream caught the attention of local environmental activists, who noticed the smell in the area.
“The other day we came here you would think it was a beer pub that hadn’t opened its doors for three or four days,” activist Carroll Cox told local Hawaii News Now. She also contacted the Department of Health about the issue.
Local media took samples from the unusual stream and had them checked at a private laboratory. It tested positive for alcohol, containing 1.2% percent of the substance in its waters – nearly a quarter the content in regular beer and strong enough to cause a buzz.
Local health authorities got involved, and an investigation into the source of contamination was launched. It was learned that the stream was coming from a drain pipe that was traced back to a warehouse of Hawaii’s largest liquor distributor, Paradise Beverages. Its representatives told local media they were working with officials to eliminate a possible spill, with the booze river apparently closing its free drinks service.
Behind the Headlines brings you expert perspectives on today’s headlines by telling you more than what happened, but also what it means. You can also listen to The Cipher Brief’s Daily Open-Source Collection Podcast wherever you listen to podcasts.
Jack Devine, Former Acting Director, National Clandestine Service, CIA
Cipher Brief Expert Jack Devine, a 32-year CIA veteran. Devine served as both Acting Director and Associate Director of CIA’s operations from 1993-1995. He is a founding partner and President of The Arkin Group, which specializes in international crisis management, strategic intelligence and investigative research. Devine is the author ofSpymaster’s Prism: The Fight Against Russian Aggression.
Russia’s multi-pronged support of Myanmar is a microcosm of its strategy in Southeast Asia.
In the months since Myanmar’s February military coup, Russia and China have been the junta’s most powerful allies, but Russia has exploited regional instability to position itself as a third path between China and the West. While China was closer with the former Myanmar government than the military, it was also concerned about the government’s ties with the West and potential interference in its development efforts, particularly its Belt and Road Initiative. Russia, on the other hand, doesn’t depend on stability in Southeast Asia to the same degree as China and can instead take advantage of warring factions. Last month, on his first trip outside of the immediate region since February, Myanmar’s junta leader Min Aung Hlaing went to Moscow to meet with high-level Russian defense officials instead of heading to Beijing. Hlaing has reportedly visited Russia seven times within the past decade and previously stated that over 6,000 Myanmar officers have studied at Russian military academies. According to data from the Stockholm International Peace Research Institute (SIPRI), Russia was responsible for almost 40% of arms sales to Myanmar from 1999-2018, second only to China. SIPRI data further indicates that Russia has been Southeast Asia’s largest arms supplier over the past two decades, counting Vietnam and Laos as top customers. But Russia is offering the region more than arms and has promised Myanmar two million Covid-19 vaccines and assistance in the nation’s own vaccine production efforts. Russia has also been trying to expand free trade agreements between its Eurasian Economic Union (EAEU) and Southeast Asian countries, most recently getting Indonesia to sign on to the deal. Stepping even further into soft power efforts, last week Russia’s foreign minister met with his Bangladeshi counterpart and agreed to encourage Myanmar to engage in dialogue with Bangladesh on the Rohingya crisis.
Get your free daily Open-Source Collection report in The Cipher Brief newsletter or take it on the go as a podcast. Listen here or wherever you listen to podcasts.
Leftist, former schoolteacher Pedro Castillo is declared President of a divided Peru, projected economic growth could play in his favor.
Peru, like many of its neighbors, has been battling the triple and interwoven threat of Covid-19, social unrest, and severe economic downturn. But for the past several years Peru has also been challenged by sharp divisions between its executive and legislative powers. Last November, Peru’s unicameral legislature voted to impeach then-President Martín Vizcarra, citing mismanagement of the pandemic and corruption, in a move that outraged thousands. The June presidential elections were likewise fraught. Castillo’s right-wing rival Keiko Fujimori, who is also under investigation for corruption, alleged electoral fraud and the Peruvians initiated a six-week long investigation, eventually finding Castillo the rightful victor. The EU, U.S. and 14 electoral missions deemed the elections legitimate, and the U.S. called the election a “model of democracy” for the region. Castillo, who previously worked as an elementary school teacher and has never held public office, will be greeted by a political establishment that is almost entirely against him. Peruvian citizens are also deeply divided, and many urban elites reportedly moved their money overseas out of fear for Castillo’s economic policies. But Castillo’s Peru Libre party holds fewer than 40 of 130 seats in the legislature and Castillo has already recruited several moderate advisors. Further, he has backed away from talk of nationalizing Peru’s lucrative multinational mining, oil, gas, and hydrocarbon companies, instead pledging to raise taxes on mining firms. Prices of copper and gold, two of Peru’s most critical exports, remain high and Covid-related trade obstacles are expected to ease over the coming months. While it is uncertain how effective Castillo will be, or where he will ultimately fall on his policies, positive projections for Peru’s export-based economy will likely play in his favor.
The Cipher Brief hosts private briefings with the world’s most experienced national and global security experts. Become a member today.
Enjin becomes first blockchain platform to gain acceptance into the United Nations Global Compact, signaling widespread range of corporate sustainability efforts.
On Tuesday, Enjin, an innovative blockchain technology company focused on non-fungible tokens (NFTs), became the first such company to join the United Nations Global Compact. Upon admission, Enjin stated that it hopes to use NFTs to promote sustainability and equality in line with the UN pact that encourages businesses and firms worldwide to adopt more environmentally friendly and socially responsible practices. NFTs have surged in popularity in the past two years, and during the first quarter of 2021 NFT sales reportedly exceeded US $2 billion. In essence, an NFT is a way to prove ownership of a unique virtual item. It’s a unit of data that’s stored on a blockchain, or digital ledger, that certifies exclusive ownership of digital files ranging from photos to sports trading cards. Enjin, which is headquartered in Singapore, has focused its NFT efforts on games and apps and is reportedly able to operate with a lower carbon footprint than Bitcoin due to a slimmed-down verification model that requires less energy. This week, the UN Global Compact not only included Enjin as a member, but gave the company its highest membership rank, sending a signal that it’s interested in promoting such an environmental effort by crypto and blockchain entrepreneurs. For its part, Enjin has stated that it wants to employ the technology in carbon capture companies, fighting climate change in the process. The Head of the UN AI and Robotics Center remarked that during the global struggle to recover from the pandemic we should take advantage of new technologies like AI and blockchain to better equip ourselves for the future.
Read more expert-driven national security insights, perspective and analysis in The Cipher Brief
